Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2019

...

Christophe-Raphaël Ganet

Boiron : Résultat 2018 en baisse - Pas de momentum spécifique - Peu d’éclairage sur 2019 à ce stade

>Baisse (un peu plus marquée que prévu) du ROC : -15% - Le ROC affiche un repli de 15,2%, à 106 M€. Le RN recule de 26,6%, à 9,5% du CA, intégrant une provision de 9,2 M€ pour contrôle fiscal en cours (hors cet impact, le RN représenterait 11% du CA, soit –14,7%).Le dividende prévu serait de 1,45 € (Oddo : 1,43 €).Aucune guidance.2018 : année blanche… – 2019: pas de guidance ou d’indication - En attendant la réunion, on peut dire :1- Le...

BOIRON SA sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of BOIRON SA (FR), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 1, 2019, the closing price was EUR 55.60 and its potential was estimated at EUR 58.38.

Christophe-Raphaël Ganet

Boiron : Q4 2018 sales: still a mixed bag

>Q4 still lacklustre: -0.7% - The Q4 sales came in at € 167.8m, i.e. -0.7% (-0.3% estimated l-f-l). Full-year sales came to € 604.2m, down 2.2% and -0.8% l-f-l (volumes effect: -€ 11m - price effect: +€ 6m – forex: -€ 8m) with the consensus forecast at € 603.5m. The company expected underlying operating profit to be lower than in 2017, due in particular to the rise in transport costs (express deliveries by plane), the US and the rise in amortisation (capacity investme...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2019

...

Christophe-Raphaël Ganet

Boiron : Résultat 2018 en baisse - Pas de momentum spécifique - Peu d’éclairage sur 2019 à ce stade

>Baisse (un peu plus marquée que prévu) du ROC : -15% - Le ROC affiche un repli de 15,2%, à 106 M€. Le RN recule de 26,6%, à 9,5% du CA, intégrant une provision de 9,2 M€ pour contrôle fiscal en cours (hors cet impact, le RN représenterait 11% du CA, soit –14,7%).Le dividende prévu serait de 1,45 € (Oddo : 1,43 €).Aucune guidance.2018 : année blanche… – 2019: pas de guidance ou d’indication - En attendant la réunion, on peut dire :1- Le...

Christophe-Raphaël Ganet

Boiron : Q4 2018 sales: still a mixed bag

>Q4 still lacklustre: -0.7% - The Q4 sales came in at € 167.8m, i.e. -0.7% (-0.3% estimated l-f-l). Full-year sales came to € 604.2m, down 2.2% and -0.8% l-f-l (volumes effect: -€ 11m - price effect: +€ 6m – forex: -€ 8m) with the consensus forecast at € 603.5m. The company expected underlying operating profit to be lower than in 2017, due in particular to the rise in transport costs (express deliveries by plane), the US and the rise in amortisation (capacity investme...

Christophe-Raphaël Ganet

Boiron : CA T4 2018: encore pas mal de contraste

>T4 toujours atone : -0,7% - Le CA T4 se situe à 167,8 M€, soit -0,7% (-0,3%e lfl.).Sur l’année, le CA se monte 604,2 M€ en baisse de 2,2% et -0,8% lfl. (effet volume : -11 M€ - effet prix : +6 M€ – FX : -8 M€), le CS attendait 603,5 M€e.La société prévoit un ROC inférieur à celui de 2017, notamment en raison des frais de transport en hausse (livraisons express par avion), aux USA et de la hausse des amortissements (investissements capacitaires depuis 5 ans ...

1 director bought

A director at Boiron bought 441 shares at 68.800EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Anis Zgaya ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor

ODDO BHF Small & MIDCAP MORNING NEWS - 01/25/2019

...

Anis Zgaya ...
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor

ODDO BHF Small & MIDCAP MORNING NEWS - 25/01/2019

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

BOIRON SA sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of BOIRON SA (FR), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 1, 2019, the closing price was EUR 55.60 and its potential was estimated at EUR 58.38.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch